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Figure S1. 1H NMR spectrum of RhDPA-Cy3. The spectrum was collected in deuterated 
acetonitrile at room temperature.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. 13C NMR spectrum of RhDPA-Cy3. The spectrum was collected in deuterated 
acetonitrile at room temperature 
NH3
Rh
N
H
H
N
RhDPA-Cy3
4+
4Cl
O
N
N
N
N
N
O
O
H
N
NH3
NH3Rh
N
H
H
N
RhDPA-Cy3
O
N
N
N
N
N
O
O
H
N
NH3
NH3
4+
4Cl
Rh
N
H
H
N
RhDPA-Cy3
4+
4Cl
O
N
N
N
N
N
O
O
H
N
NH3
NH3
Rh
N
H
H
N
RhDPA-Cy3
O
N
N
N
N
N
O
O
H
N
NH3
NH3
4+
4Cl
 S4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3. 13H NMR spectrum of RhPPO-Cy3. The spectrum was collected in deuterated 
acetonitrile at room temperature. The compound was obtained as a diastereomeric mixture and 
characterized as such. 
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Figure S4. TOF-MS ES+ characterization of RhDPA-Cy3. (Upper) Experimental spectrum of 
RhDPA-Cy3; (Lower) Calculated spectra for m/z 538.2; 613.1; 1225.3. When the spectrum was 
recorded, the compound was not anion exchanged to its chloride salt. Therefore, we observe the 
triflate salt in the experimental spectrum.  
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Figure S5. TOF-MS ES+ characterization of RhPPO-Cy3. (Upper) Calculated m/z = 1177.4449 
for [M – 2H]+; (Lower) Experimental spectrum with m/z = 1177.3186. [M – 2H]+ is assigned to 
the complex with both imines deprotonated, indicated with an arrow in the chemical structure.  
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Figure S6. MS-ESI+ characterization of RhPPO-Cy3 using an LTQ spectrometer. The spectrum 
was recorded after HPLC purification of RhPPO-Cy3. Insets are zooms of m/z 393.67 and m/z 
589.83 peak; m/z 393.67 (100%) corresponds to [M]3+ (both imines on chrysi ligand are 
protonated); m/z 589.83 (77%) corresponds to [M – H]2+ (only one imine is protonated). 
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Figure S7. HPLC trace of RhPPO-Cy3 after purification. The HPLC purification was followed 
using three different wavelengths: at 270 nm, 410 nm (marking the absorption of rhodium 
complex center), and 550 nm (marking the absorption of Cy3 dye). Mobile phase: 85/15 to 50/50 
to 85/50 (0.1% trifluoroacetic acid in water)/acetonitrile eluting over 40 minutes.  
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Figure S8. Absorption profile of RhPPO-Cy3, and its models Cy3-linker and RhPPO-Hdpa. 
Spectra collected in Tris buffer (5mM Tris, 200 mM NaCl, pH 7.4) at room temperature. 
[RhPPO-Cy3]; [Cy3-linker]; [RhPPO-Hdpa] = 10 µM. Absorption maxima for RhPPO-Cy3 (in 
Tris 5 mM, 200 mM NaCl, pH 7.4): l(552nm) e = 61,000 M-1 cm-1; l(267nm) e = 28,000 M-1 cm-
1. Inset: Emission of RhPPO-Cy3 at 1µM free in Tris buffer solution (5mM Tris, 200 mM NaCl, 
pH 7.4) with lmax = 565 nm, or in the presence of 1 eq. MM dsDNA with lmax = 570 nm. The 
synthesis and characterization of RhPPO-Hdpa and Cy3-linker have been previously reported.1,2 
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Figure S9. Evaluation of cytotoxicity of RhPPO-Cy3 at different time points. The cells were 
treated with RhPPO-Cy3 at the concentrations indicated, and then cell viability was assessed 
with a Cell Titer-glo assay. (A) Dose response curve of cell viability assessed after 24 hours 
incubation with RhPPO-Cy3; (B) dose response curve assessed after 48 hours incubation with 
RhPPO-Cy3. Error bars are representative of three replicates. 
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Figure S10. RhPPO-Cy3 shows preferential cytotoxicity for MMR-deficient CRC cell lines. A 
panel of MMR-deficient and MMR-proficient CRC cell lines was treated with RhPPO-Cy3 in a 
dose response. After 72 hours incubation, cell viability was assessed with a Cell Titer-glo assay. 
Duplicate samples were analyzed in each experiment. (A) Dose response curves from a 
representative experiment are shown. In blue are MSS cell lines; in red are MSI cell lines.  (B) 
Comparison of EC50 values for the MSS and MSI cell lines.  
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Figure S11. RhPPO-Cy3 causes DNA damage. HCT-116 O and HCT-116 N cells were treated 
with 5 µM RhPPO-Cy3 or cisplatin for 24 hours, and then analyzed for DNA damage using a 
neutral Comet assay. Cells were embedded in agarose, denatured and analyzed by TBE gel 
electrophoresis. Cell nuclei and comet tails were visualized with a Vista Green fluorescent dye. 
Representative images are shown. Scale bar, 20 µM. 
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